6 May 2024
Corporate Presentation for Investors
Read more
Upcoming Investor Events
Learn More
THE LANCET :
FRESCO-2, a global Phase III study of fruquintinib in refractory metastatic colorectal cancer
Learn More
THE LANCET HAEMATOLOGY:
Sovleplenib for primary immune thrombocytopenia patients in China
Learn More
European Lung Cancer Congress 2022
Final OS results and subgroup analysis of savolitinib Phase II study in METex14+ NSCLC
Learn More
Latest News
26 Apr 2024HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by TakedaRead more 5 Apr 2024HUTCHMED Highlights Data to be Presented at AACR Congress 2024Read more 2 Apr 2024HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review StatusRead more
28 Mar 2024HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLCRead more 22 Mar 2024HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in ChinaRead more 28 Feb 2024HUTCHMED Reports 2023 Full Year Results and Provides Business UpdatesRead more 7 Feb 2024HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series SessionRead more See all
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
LONDON AIM
13
HKEX
13
IN-HOUSE DISCOVERED
CLINICAL STAGE CANCER
DRUG CANDIDATES
CLINICAL STAGE CANCER
DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
PRODUCTS IN CHINA
1
APPROVED & MARKETED
PRODUCT IN THE U.S.
PRODUCT IN THE U.S.
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13 REGISTRATION STUDIES
INCLUDING 13 REGISTRATION STUDIES
5,000
PERSONNEL ACROSS
THE GROUP
THE GROUP
OUR SCIENCE
Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.
FOLLOW HUTCHMED ON SOCIAL MEDIA
